Literature DB >> 34080564

Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study.

Erica Morse1, Ingrid A Binswanger2, Emmeline Taylor3, Caroline Gray4, Matthew Stimmel5, Christine Timko6, Alex H S Harris7, David Smelson8, Andrea K Finlay9.   

Abstract

BACKGROUND: Veterans involved in the legal system have a high risk of overdose mortality but limited utilization of medications for opioid use disorder (MOUD). To increase the use of MOUD in Veterans Health Administration (VHA) facilities and reduce overdose mortality, the VHA should incorporate strategies identified by legal-involved veterans to improve quality of care and ensure that their patients' experiences are integrated into care delivery. This study aims to determine strategies to increase use of MOUD from the perspective of legal-involved veterans with a history of opioid use or opioid use disorder (OUD).
METHODS: Between February 2018 and March 2019, we conducted semistructured interviews with 18 veterans with a history of opioid use or OUD and legal involvement (15 men and 3 women; mean age 41, standard deviation 13, range 28-61). Veterans were from 9 geographically dispersed United States VHA facilities. The study analyzed verbatim transcripts using the framework method. The primary focus was themes that represented legal-involved veteran-identified strategies to improve the use of MOUD.
RESULTS: The 18 veterans interviewed had legal involvement directly related to their opioid use and most (n = 15; 83%) had previously used MOUD. Veteran-identified strategies to improve access to and use of MOUD included: (1) VHA should provide transportation or telehealth services; (2) legal agencies should increase access to MOUD during incarceration; (3) the VHA should reduce physician turnover; (4) the VHA should improve physician education to deliver compassionate, patient-centered treatment; (5) the VHA should improve veteran education about MOUD; and (6) the VHA should provide social support opportunities to veterans.
CONCLUSIONS: Legal-involved veterans provided strategies that can inform and expand MOUD to better meet their needs and the treatment needs of all patients with OUD. The VHA should consider incorporating these strategies into care, and should evaluate their impact on patients' experience, initiation of and retention on medications, and overdose rates. Published by Elsevier Inc.

Entities:  

Keywords:  Criminal justice; Opioid-related disorders; Pharmacotherapy; Veterans

Mesh:

Year:  2021        PMID: 34080564      PMCID: PMC8380634          DOI: 10.1016/j.jsat.2021.108353

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  59 in total

1.  Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.

Authors:  Andrea K Finlay; Jessie J Wong; Laura S Ellerbe; Anna Rubinsky; Shalini Gupta; Thomas R Bowe; Eric M Schmidt; Christine Timko; Jennifer L Burden; Alex H S Harris
Journal:  J Stud Alcohol Drugs       Date:  2018-11       Impact factor: 2.582

2.  Impact of Transportation Interventions on Health Care Outcomes: A Systematic Review.

Authors:  Eli M Solomon; Holly Wing; John F Steiner; Laura M Gottlieb
Journal:  Med Care       Date:  2020-04       Impact factor: 2.983

3.  Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Emily Scherer; Lisa A Marsch
Journal:  J Subst Abuse Treat       Date:  2020-01-21

4.  Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps.

Authors:  Jessica J Wyse; Adam J Gordon; Steven K Dobscha; Benjamin J Morasco; Elizabeth Tiffany; Karen Drexler; Friedhelm Sandbrink; Travis I Lovejoy
Journal:  Subst Abus       Date:  2018       Impact factor: 3.716

5.  Use of Veterans Health Administration Mental Health and Substance Use Disorder Treatment After Exiting Prison: The Health Care for Reentry Veterans Program.

Authors:  Andrea K Finlay; Matthew Stimmel; Jessica Blue-Howells; Joel Rosenthal; Jim McGuire; Ingrid Binswanger; David Smelson; Alex H S Harris; Susan M Frayne; Tom Bowe; Christine Timko
Journal:  Adm Policy Ment Health       Date:  2017-03

6.  Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.

Authors:  Bobbi Jo H Yarborough; Scott P Stumbo; Dennis McCarty; Jennifer Mertens; Constance Weisner; Carla A Green
Journal:  Drug Alcohol Depend       Date:  2016-01-06       Impact factor: 4.492

7.  Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders.

Authors:  Angela Russolillo; Akm Moniruzzaman; Lawrence C McCandless; Michelle Patterson; Julian M Somers
Journal:  Addiction       Date:  2017-11-19       Impact factor: 6.526

8.  Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.

Authors:  Alex H S Harris; Thomas Bowe; Hildi Hagedorn; Andrea Nevedal; Andrea K Finlay; Risha Gidwani; Craig Rosen; Chad Kay; Melissa Christopher
Journal:  Addict Sci Clin Pract       Date:  2016-09-15

9.  Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.

Authors:  Margo E Godersky; Andrew J Saxon; Joseph O Merrill; Jeffrey H Samet; Jane M Simoni; Judith I Tsui
Journal:  Addict Sci Clin Pract       Date:  2019-03-13

10.  Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic.

Authors:  Marcus Castillo; Brianna Conte; Sam Hinkes; Megan Mathew; C J Na; Ainhoa Norindr; David P Serota; David W Forrest; Amar R Deshpande; Tyler S Bartholomew; Hansel E Tookes
Journal:  Harm Reduct J       Date:  2020-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.